

## Response to: 'Case of postpartum axial spondyloarthritis' by Furuhashi *et al*

We were pleased to read the correspondence of Furuhashi *et al*<sup>1</sup> who highlighted the importance of considering coexisting risk factors when diagnosing axial spondyloarthritis (ax-SpA) in early postpartum women. The authors correctly pointed out that patients with inflammatory bowel disease are more likely to develop ax-SpA due to common pathogenic mechanisms.<sup>2</sup> In fact, the presence of Crohn's disease or ulcerative colitis is part of the Assessment of SpondyloArthritis international Society criteria for the diagnosis of ax-SpA.<sup>3</sup>

In our study, on the prevalence of bone marrow oedema (BME) at the sacroiliac joint (SIJ) in postpartum women,<sup>4</sup> we excluded those with known risk factors for developing ax-SpA, such as family or patient history of inflammatory diseases. The exclusion of women with known risk factors for developing ax-SpA was deemed important to eliminate potential confounding factors, and hence ascertain whether observations of sacroiliitis were triggered by, or related to, pregnancy and childbirth as opposed to other aetiologies.

In our experience, women with inflammatory bowel disease who have low back pain within the first 6 months after delivery should be assessed using MRI to identify the causes of pain, which could include infections or degenerative diseases. However, we believe that BME at the SIJ observed in an MRI taken during the early postpartum period is insufficient to diagnose ax-SpA, since BME at the SIJ may be merely transient and could disappear over time. It is also important to note the limitations of MRI for the diagnosis of ax-SpA, due to limited sensitivity and specificity of detecting 'suggestive BME' lesions, and the role/necessity of conventional radiography for the standardisation and contextual evaluation.<sup>5</sup> While response to tumour necrosis factor inhibitors, such as adalimumab, can confirm diagnosis and relieve symptoms, immunosuppressive drugs are associated with a number of adverse events. We endeavour to improve the efficacy of clinical and imaging diagnostic tools to prescribe the most appropriate treatment and avoid such adverse events, especially in patients that are unlikely to benefit from immunosuppressive drugs.

Adel Hoballah,<sup>1</sup> Cédric Lukas,<sup>2</sup> Christophe Leplat,<sup>1</sup> Patrice Taourel,<sup>1</sup> Jean-Baptiste Pialat,<sup>3</sup> Nicolas Sans,<sup>4</sup> Sonia Ramos-Pascual<sup>5</sup>,  
Mo Saffarini,<sup>5</sup> Catherine Cyteval<sup>1</sup>

<sup>1</sup>Osteoarticular Medical Imaging Section, Department of Medical Imaging, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France

<sup>2</sup>Department of Rheumatology, University Hospital Centre Montpellier, Montpellier, Languedoc-Roussillon, France

<sup>3</sup>Department of Radiology, Groupement Hospitalier Edouard Herriot, Lyon, Rhône-Alpes, France

<sup>4</sup>Department of Radiology, Toulouse University Hospital, Paul Sabatier University, Toulouse, Occitanie, France

<sup>5</sup>ReSurg SA, Nyon, Vaud, Switzerland

**Correspondence to** Dr Sonia Ramos-Pascual, ReSurg SA, Nyon 1560, Vaud, Switzerland; journals@resurg.com

**Handling editor** Josef S Smolen

**Contributors** All authors contributed to this response letter. The first draft of the letter was written by SRP and MS. All authors approved the final letter.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Hoballah A, Lukas C, Leplat C, *et al*. *Ann Rheum Dis* 2022;**81**:e172.

Received 3 August 2020

Accepted 3 August 2020

Published Online First 21 August 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-218587>

*Ann Rheum Dis* 2022;**81**:e172. doi:10.1136/annrheumdis-2020-218687

### ORCID iD

Sonia Ramos-Pascual <http://orcid.org/0000-0002-0409-613X>

### REFERENCES

- 1 Furuhashi K, Honda N, Miyoshi Y, *et al*. Case of postpartum axial spondyloarthritis. *Ann Rheum Dis* 2022;**81**:e171.
- 2 Fragoulis GE, Liava C, Daooussis D, *et al*. Inflammatory bowel diseases and spondyloarthropathies: from pathogenesis to treatment. *World J Gastroenterol* 2019;**25**:2162–76.
- 3 Sieper J, Rudwaleit M, Baraliakos X, *et al*. The assessment of spondyloarthritis International Society (ASAS) Handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis* 2009;**68** Suppl 2:ii1–44.
- 4 Hoballah A, Lukas C, Leplat C, *et al*. MRI of sacroiliac joints for the diagnosis of axial spa: prevalence of inflammatory and structural lesions in nulliparous, early postpartum and late postpartum women. *Ann Rheum Dis* 2020;**79**:1063–9.
- 5 Lukas C, Cyteval C, Dougados M, *et al*. MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations 'Not everything that glitters is gold (standard)'. *RMD Open* 2018;**4**:e000586.